Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 1038-1044

  Ibrahim, Nuhad K ^a   Desai, Neil ^c   Legha, Sewa ^a   Soon Shiong, Patrick ^c   Theriault, Richard L ^a   Rivera, Edgardo ^a   Esmaeli, Bita ^b   Ring, Sigrid E ^a   Bedikian, Agop ^a   Hortobagyi, Gabriel N ^a   Ellerhorst, Julie A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c American BioScience Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; NANOPARTICLE; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRY SKIN; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; KERATOPATHY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CASTOR OIL; CHEMISTRY, PHARMACEUTICAL; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; NERVOUS SYSTEM DISEASES; PACLITAXEL; PARTICLE SIZE; STOMATITIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0036096946     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. The taxanes: An update
2. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
3. Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
4. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26
5. Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma
6. Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients
7. Pharmacology and toxicology of Cremophor EL diluent
8. Hypersensitivity reactions from taxol
9. Paclitaxel (taxol)
10. Patient care issues: The management of paclitaxel-related toxicities
11. Potential neurotoxicity of the solvent vehicle for cyclosporine
12. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers
13. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel
14. Protein-based nanoparticles for drug delivery of paclitaxel
15. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs
16. Measurement of cremophor EL following taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype
17. Disposition of cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo
18. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules
19. Phase I clinical and pharmacokinetic study of taxol
20. Phase I trial of taxol in patients with advanced cancer
21. Ocular toxicity from high-dose 1-β-D-arabinofuranosylcytosine
22. Ocular toxicity secondary to paclitaxel in two lung cancer patients
23. 2
24. Ocular toxicity and cancer chemotherapy
25. Weekly docetaxel (Taxotere) for metastatic breast cancer: A phase II trial
26. Pharmacokinetics of taxanes
27. The pharmacokinetics of a 1-h paclitaxel infusion
28. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
29. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review